Literature DB >> 28469110

Unusual Ovarian Cancer Relapse Managed by Nivolumab in a Long-term Surviving Patient with PD-L1 Mutation.

Jie Yang1, Jun-Jun Yang1, Jun Zhao1, Tong Ren1, Feng-Zhi Feng1, Xi-Run Wan1, Yang Xiang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28469110      PMCID： PMC5421185          DOI： 10.4103/0366-6999.204922

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN： 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  3 in total

1.  Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988.

Authors:  E Reed; C S Zerbe; O W Brawley; A Bicher; S M Steinberg
Journal:  Am J Clin Oncol       Date:  2000-04       Impact factor: 2.339

2.  PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.

Authors:  John R Webb; Katy Milne; David R Kroeger; Brad H Nelson
Journal:  Gynecol Oncol       Date:  2016-03-16       Impact factor: 5.482

3.  PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.

Authors:  Seiichi Ikeda; Tatsuro Okamoto; Shinji Okano; Yuichiro Umemoto; Tetsuzo Tagawa; Yosuke Morodomi; Mikihiro Kohno; Shinichiro Shimamatsu; Hirokazu Kitahara; Yuzo Suzuki; Takatoshi Fujishita; Yoshihiko Maehara
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.